| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President and CEO | CEO - Elect
1 company
Julie So-Young Kim is President and CEO at TKPHF. Julie So-Young Kim's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $16.4M at current prices.
The TKPHF filings lean toward selling, a net 89,090 shares.
Julie So-Young Kim has 3 Form 4 filings on record from April 2026 to August 2026, all as President and CEO at Takeda Pharmaceutical (TKPHF), 2026.
The 7 reported transactions were 3 stock awards, 3 option or other derivative awards and 1 open-market sale.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $1.5M.
The only open-market sale was 89,090 shares of TKPHF at an average $17.10 on August 10, 2026, about $1.5M.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | TKPHF Takeda Pharmaceutical Company Limited | President and CEO | Sell | 89,090 | $17.10 | $1,523,439.00 | -18.5% |